Autoimmune diagnostic test maker Exagen Q2 revenue up more than expected

Exagen

29/07/2025 13:08

Overview

Exagen Q2 2025 revenue grows 14% yr/yr, beating analyst expectations

Company reports Q2 net loss of $4.4 mln despite revenue growth

Exagen strengthens balance sheet with $20.2 mln public offering and loan facility

Outlook

Exagen expects 2025 full-year revenue between $65 mln and $70 mln

Company anticipates positive adjusted EBITDA in Q4 at high end of FY revenue forecast

Result Drivers

TEST VOLUME INCREASE - AVISE CTD test volume grew 14% compared to Q1 2025, contributing to revenue growth

HIGHER ASP - Trailing twelve-month average selling price for AVISE CTD tests increased by $27 over Q2 2024

BALANCE SHEET STRENGTHENING - Co closed $20.2 mln public offering and new loan facility, boosting cash reserves

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$17.20 mln
$16.30 mln (6 Analysts)
Q2 EPS
-$0.21
Q2 Net Income
-$4.44 mln
Q2 Operating Expenses
$13.02 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Exagen Inc is $8.50, about 13.1% above its July 28 closing price of $7.39

Press Release: ID:nGNX2rzGV

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)